Upper gastroduodenal ulceration in arthritis patients treated with celecoxib

Annals of Pharmacotherapy

Volumn 35, Issue 7-8, 2001, Pages 829-834

  Ashcroft, D M ^a   Chapman, S R ^a   Clark, W K ^a   Millson, D S ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

Celecoxib; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

CELECOXIB; DICLOFENAC; IBUPROFEN; NAPROXEN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS;

EID: 0034911677     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10382     Document Type: Article

References (14)

1. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial
2. Cost of NSAID adverse effects to the UK National Health Service
3. COX-2 inhibitors
4. Summary of evidence of Cox-2 inhibitors
5. Meta-analysis in clinical trials
6. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
7. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
8. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
9. Cyclooxygenase 2 selective inhibitors: Panacea or flash in the pan?
10. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
11. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
12. Outcomes studies of drug induced ulcer complications: Do we need them and how should they be done?